预约演示

AstraZeneca moves forward with a $360M API plant in Ireland

2023-02-09

交易

AstraZeneca’s application for a $360 million manufacturing site in a Dublin suburb is yet to be accepted, but it is making progress. The facility, which AstraZeneca first announced in 2021, will be built at an Alexion site in the suburb of Blanchardstown and produce APIs for small molecule therapies. Documents submitted to the Fingal County Council’s Planning and Strategic Infrastructure Department give more details about the project. According to the submission, the manufacturing building will be five stories and 10,315 square meters, which is over 111,000 square feet. The construction will also include a two-story chemical materials storage facility and a four-story laboratory building that will be around 5,148 square meters, or over 55,000 square feet. Storage tanks and an extension to the existing warehousing space are among other enhancements slated for the site, which is expected to employ over 100 new workers. According to a report from The Irish Times, the new facility will start construction in April and is anticipated to come online around the first quarter of 2026. The report from The Irish Times also states that the council will make a final decision on the project later this month. “The new plant will allow for late-stage development and early commercial supply, adopting state-of-the-art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility,” said an AstraZeneca spokesperson in an email to Endpoints News. It’s not just AstraZeneca that is bullish on the project. The Industrial Development Agency of Ireland is positive about the forward motion for the facility and sees it as a “testament” to the life science and pharma manufacturing ecosystem in the Emerald Isle. “Competition for Foreign Direct Investment (FDI) is more intense than ever, and all investment is hard won and very welcome. This investment, creating over 100 highly skilled jobs, including scientists and engineers, clearly demonstrates confidence in the capabilities of the Irish pharmaceutical workforce,” IDA said in a statement to Endpoints. This project is also not the first investment in the Blanchardstown site. Last year, Alexion announced it would make a €65 million ($69.4 million) investment in the site as well as another manufacturing facility in Athlone. Ireland was on a roll in 2022, with several large pharma companies announcing multimillion-dollar projects, with names such as Pfizer，Ipsen, AbbVie and J&J all placing down investments.

内容来源于网络，如有侵权，请联系删除。

机构